New combo therapy aims to shrink Hard-to-Treat bowel tumors before surgery
NCT ID NCT07403877
First seen Feb 12, 2026 · Last updated Jun 09, 2026 · Updated 19 times
Summary
This study tests three treatment plans for people with a specific type of colorectal cancer (MSI-H/dMMR) that has spread locally but not to distant organs. The goal is to see if combining two immunotherapy drugs, or adding radiation to one immunotherapy drug, works better than one immunotherapy drug alone at shrinking tumors before surgery. About 114 adults will take part, and those with low rectal cancer may avoid surgery if the tumor completely disappears after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (MSI-H) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, China
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.